BiotechTube

Acalabrutinib in combination with BR + Acalabrutinib in combination with VR

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mantle Cell Lymphoma (MCL)

Conditions

Mantle Cell Lymphoma (MCL)

Trial Timeline

Apr 20, 2016 → Aug 20, 2027

NCT ID
NCT02717624

About Acalabrutinib in combination with BR + Acalabrutinib in combination with VR

Acalabrutinib in combination with BR + Acalabrutinib in combination with VR is a phase 1 stage product being developed by AstraZeneca for Mantle Cell Lymphoma (MCL). The current trial status is active. This product is registered under clinical trial identifier NCT02717624. Target conditions include Mantle Cell Lymphoma (MCL).

What happened to similar drugs?

1 of 6 similar drugs in Mantle Cell Lymphoma (MCL) were approved

Approved (1) Terminated (1) Active (4)
✅Acalabrutinib capsuleAstraZenecaApproved
🔄Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
🔄Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
🔄Acalabrutinib + Bendamustine + Rituximab + PlaceboAstraZenecaPhase 3
🔄Sonrotoclax + Zanubrutinib + PlaceboBeOne MedicinesPhase 3
❌parsaclisib + rituximab + bendamustine + PlaceboIncytePhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02717624Phase 1Active

Competing Products

20 competing products in Mantle Cell Lymphoma (MCL)

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
42
Obinutuzumab + Glofitamab + PirtobrutinibEli LillyPhase 2
42
enzastaurinEli LillyPhase 2
35
AbemaciclibEli LillyPhase 2
35
Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
44
Pirtobrutinib + Rituximab + VenetoclaxEli LillyPhase 2
42
Pirtobrutinib and rituximabEli LillyPhase 2
42
gemcitabine + mitoxantrone + rituximabEli LillyPhase 2
35
Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
40
VenetoclaxAbbViePhase 2
35
Ibrutinib + VenetoclaxAbbViePhase 2
35
ABT-199 and Ibrutinib CombinationAbbViePhase 1
29
Venetoclax Oral Tablet [Venclexta]AbbViePhase 2
27
Acalabrutinib capsuleAstraZenecaApproved
43
Acalabrutinib + Venetoclax + ObinutuzumabAstraZenecaPhase 1/2
39
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapyAstraZenecaPhase 2
42
Acalabrutinib + Venetoclax + RituximabAstraZenecaPhase 2
39
Acalabrutinib + RituximabAstraZenecaPhase 2
42
Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment DAstraZenecaPhase 1
29
Acalabrutinib + Lenalidomide + Rituximab + ObinutuzumabAstraZenecaPhase 2
39